HEALTHCARE & MEDICARE
-
H1 2025's Digital Health Fund: Market Stable, AI Dominates and Exits Return
The digital health world showed real market traction in the first half of the year, according to a report from…
Read More » -
Kalvista drug has received FDA approval to treat acute swelling attacks in rare diseases
In rare diseases, hereditary angioedema or HAE, painful swelling attacks can occur anywhere in the body without warning. Drugs can…
Read More » -
Hospitals are investing in AI – how do they evaluate ROI?
Will artificial intelligence (AI) make money or damage hospital finance? Excitement about AI commitments has attracted billions of dollars in…
Read More » -
Episode 17 Debunked: Are Big Pharmaceuticals ready for the impact of Trump administration’s health policies?
Changes in the Trump administration’s health care policy have sparked great concerns about their short-term and long-term consequences. In their…
Read More » -
The New Future of DNA – Healthcare Blog
Kim Bellard As my own DNA-based organism, I am always fascinated by the extraordinary abilities of DNA. Not only life…
Read More » -
How Microsoft triggers innovation in rural hospitals
With the increasing threat of cybersecurity and the growing demand for digital, rural hospitals, often operated by IT crew’s skeletal…
Read More » -
Key tests for blockbuster Novartis drug failure hope to expand its use to rare vascular disorders
Novartis is in competition to expand its blockbuster explosives Cosentyx into autoimmune diseases, its only biotherapeutic option is the old…
Read More » -
Beyond the Disconnected Links: High Bets for Providers Directory Accuracy in the Times
Inaccurate provider catalogs have long been frustration for patients, providers and payers. Today, in the regulatory environment shaped by the…
Read More » -
From paid services to value-based care: results for kidney enhancement
The traditional fee-for-service (FFS) healthcare model is not suitable for meeting the complex needs of patients with chronic diseases, including…
Read More » -
With the FDA nodding in lung cancer, Dizal is now aiming for the best J&J medicines and succeeding where Takeda falls off
One of the most competitive targets in lung cancer is some kind of mutation that avoids many of the targeted…
Read More »